Everything below concerns research chemical. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-05-05. Where a claim depends on a specific study, the study is described rather than over-claimed.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine in major jurisdictions | Sold as a research chemical; legal status varies |
| Anti-doping status | Prohibited by the World Anti-Doping Agency | Listed under non-approved substances or related category |
| Typical analytical method | LC-MS/MS | Used for detection and confirmation in biological samples |
| Storage temperature | −20 °C or lower for solid | Desiccated and protected from light |
| Common solution solvents | DMSO; ethanol | Aqueous solubility is limited |
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
=== Pain === A 2026 meta-analysis concluded that people taking melatonin supplements may experience relief from musculoskeletal pain similar in magnitude to the effects of typical analgesics. Although melatonin may be considered as an adjunct option for pain relief, it had only modest effects, and the quality of evidence for efficacy was low to moderate.
=== Mechanical engineering === When a periodic force is applied to a mechanical system, it will typically reach a steady state after going through some transient behavior. This is often observed in vibrating systems, such as a clock pendulum, but can happen with any type of stable or semi-stable dynamic system. The length of the transient state will depend on the initial conditions of the system. Given certain initial conditions, a system may be in steady state from the beginning.
== Later career == Ondetti enjoyed success with his synthesis of Captopril. He remained active in research, gaining patents in 1985, 1992, and 1993. Squibb recognized his leadership skills and he received numerous promotions at Squibb. After his Captopril discovery, he was promoted to vice president of Basic Research. In the next ten years, Ondetti assumed more leadership roles in the cardiovascular and metabolic research department, culminating in his promotion to senior vice president of cardiovascular and metabolic in 1990. Ondetti retired the next year in 1991. At this time he lived in Princeton, New Jersey. In 1991, Ondetti was awarded the prestigious Perkin Medal. Ondetti was interviewed by James J. Bohning of the Chemical Heritage Foundation in 1995 for The Oral History Program at the Chemical Heritage Foundation. Miguel A. Ondetti died on August 23, 2004.
Sources: en.wikipedia.org
=== Naturally derived scaffolds === Acellular Dermis. An acellular dermis is made by removing the cells (epidermis and dermal fibroblasts) from split-thickness skin. It has two sides: one side has a basal lamina suitable for the epithelial cells, and the other is suitable for fibroblast infiltration because it has intact vessel channels. It is durable, able to keep its structure and does not trigger immune reactions (non-immunogenic). Amniotic Membrane. The amniotic membrane, the inner part of the placenta, has a thick basement membrane of collagen type IV and laminin and avascular connective tissue.
=== Pre-release === SFM was developed internally at Valve in 2005 and most of it was based on the code from the in-game demo playback tool found in Source. SFM was used to make Day of Defeat: Source trailers with effects that could not be achieved in real-time. The tool was used extensively for certain promotional materials for the release of Team Fortress 2, particularly the Meet the Team trailers. This version of SFM, which ran using Source's in-game tools framework, was unintentionally leaked during the public beta of Team Fortress 2 in September 2007. By 2010, the entire interface was re-implemented using Qt 4 and given its engine branch for further development. Before SFM was released to the public, Team Fortress 2 carried a simplified version of SFM known as the "Replay Editor", which was limited to capturing the actual events occurring throughout a player's life. It provided no ability to modify actions, repeat segments, or apply special effects beyond those already used in-game. However, arbitrary camera angles were possible, such as tracking the movements of other players in action at the time. The Replay Editor also allowed users to upload completed videos to YouTube. On June 27, 2012, SFM became available on a limited basis through Steam, the same day the final Meet the Team video "Meet the Pyro" was released. The open beta for Windows was released as of July 11, 2012. From 2011 to 2018, Valve operated a competition known as the Saxxy Awards for community-made SFM animations.
As more African-Americans are incarcerated, the more the heuristic is enforced in the eyes of the courts, which contributes to yet higher imprisonment rates among African-American children. High numbers of African American arrests and charges of possession show that although most drug users in the United States are white, blacks are the largest group being targeted as the root of the problem. Furthermore, a study by Andrew Golub, Bruce Johnson, and Eloise Dunlap affirms the racial divide in drug arrests, notably marijuana arrests, where blacks with no prior arrests (0.9%) or one prior arrest (4.3%) were nearly twice as likely to be sentenced to jail as their white counterparts (0.4% and 2.3%, respectively). Harboring such emotions can lead to a lack of will to contact the police in case of an emergency by members of African-American communities, ultimately leaving many people unprotected. Disproportionate arrests in African-American communities for drug-related offenses has not only spread fear but also perpetuated a deep distrust for government and what some call racist drug enforcement policy. Additionally, a black-white disparity can be seen in probation revocation since black probationers were revoked at higher rates than white and Hispanic probationers in studies as published under the Urban Institute.
Sources: en.wikipedia.org
Its legal status depends on the country and intended use. It is not an approved medicine in major jurisdictions. In sport, it is prohibited by anti-doping rules.
Laboratories typically use LC-MS/MS to detect SR9009 and related compounds in urine or blood. The method is sensitive but depends on sample collection timing. Confirmatory analysis follows quality-control procedures.
Solid material is generally kept cold, dry, and protected from light. Solutions are often stored in sealed containers at low temperature. Stability beyond recommended periods is not well documented.
It is a synthetic REV-ERB agonist used mainly in preclinical research. It is not an approved medicine for human use.